Medical bottles and a syringe appear with the Novor Nordisk logo displayed on the background screen.
Nurfoto | Nurfoto | Getty
Danish pharmaceutical monster Novo Nordis On Tuesday, he reduces its full -year sales and profits guidance on Tuesday by mentioning the expectations of weak growth in the United States on Tuesday.
The shares were 15% down at 12:11 pm in the afternoon, after the announcement (AM 7:12 AT).
The company has said that a low approach is less than the estimates of the increase in the US sales for its different weight loss drugs and the treatment of ozemic diabetes.
“For the Vegvi in the US, the compound of the sales, the GLP -1S, reflects the expansion and competition in the market less than expected in the market,” said a statement.
This is a developing story. Please check back for updates.
Post Comment